Do collagen supplements reduce wrinkles? What independent research actually found

The promise is specific: take a daily collagen supplement and your skin will look younger, wrinkles will fade, and ageing will slow. This claim appears on products in every UK pharmacy, backed by language like “clinically proven” and “visible results in 28 days.”

The commercial scale is substantial. In the UK, the skin supplement segment was valued at $156 million in 2024 and is projected to reach $353 million by 2033. Collagen is the single largest revenue-generating ingredient, making the state of the science worth careful examination.

Two studies have emerged within the past year. A 2025 meta-analysis concluded that no clinical evidence supports collagen supplementation for skin ageing. A 2026 independent review — the largest yet conducted — found limited, conditional benefits for a specific group of people. Neither supports what most labels claim.

Table of Contents

When the industry money is filtered out

In May 2025, Dr Seung-Kwon Myung of South Korea’s National Cancer Center and Yunseo Park of Monash University published a systematic review in The American Journal of Medicine. The review covered 23 randomised controlled trials (RCTs — studies that assign participants randomly to treatment or placebo) and 1,474 participants, assessing skin hydration, elasticity, and wrinkles.

When results from all 23 trials were pooled, collagen showed significant improvements in all three measures. That is the headline version. However, a more revealing result emerges when the trials are split by who paid for them.

In trials without pharmaceutical funding, collagen showed no significant effect on any outcome. In industry-funded trials, significant effects appeared consistently. High-quality studies showed no significant benefit, while low-quality studies did. Myung and Park’s conclusion was clear: “There is currently no clinical evidence to support the use of collagen supplements to prevent or treat skin aging.”

Myung and Park’s full paper is behind a paywall, so exactly how they classified each trial as industry-funded or independent cannot be independently verified. Three industry bodies have challenged the methodology, and their objections are addressed below.

Industry objections — and what they reveal

Unsurprisingly, industry bodies quickly challenged Myung and Park’s findings. The Collagen Stewardship Alliance claimed that several trials listed as independent had actually received ingredient supply or financial support from manufacturers. If true, the number of genuinely independent trials may be too small to support the conclusions drawn from them.

TOSLA Nutricosmetics highlighted data-entry errors: one trial was recorded at a 50 g/day dose when participants actually took approximately 5.5 g/day, and another had its study duration listed as 16 weeks when it ran for 12. GROW, the Gelatin Representatives of the World, raised a different issue: the criteria used to judge trial quality are never disclosed in the paper.

All three objections come from parties that profit from collagen sales. None undermines the central finding. TOSLA’s own rebuttal conceded that 21 of 23 trials in the dataset had some form of industry involvement. Whatever errors exist in the methodology, that underlying condition is not disputed.

The UK regulatory picture reinforces this. The Great Britain Nutrition and Health Claims Register authorises no health claims for collagen supplements. The Advertising Standards Authority has upheld multiple complaints against collagen marketing — ruling against Kollo Health Ltd in November 2023, and ordering Dermacoll in 2019 to remove claims that its drink could “combat skin ageing” and “plump and fill out fine lines.”

The largest independent study: better news, narrower audience

In February 2026, Anglia Ruskin University (ARU) published the most comprehensive independent analysis of collagen supplementation to date. Led by Professor Lee Smith, Professor of Public Health, it combined the results of 16 previous systematic reviews, 113 individual trials, and approximately 8,000 participants worldwide. It received no industry funding.

The results were more encouraging than those of Myung and Park, but also more conditional. Skin elasticity and hydration improved, while skin roughness did not. Benefits grew with longer supplementation — a few weeks produced less improvement than several months of consistent use. “Collagen is not a cure-all,” Professor Smith stated, “but it does have credible benefits when used consistently over time, particularly for skin and osteoarthritis.”

Who benefits most is the detail most product marketing omits. The review found the strongest evidence for postmenopausal women and people with UV-damaged skin. Products routinely marketed to all adults over 25 target a population the independent evidence does not specifically support.

Dr Tamara Griffiths, President of the British Association of Dermatologists and Honorary Lecturer at the University of Manchester, identified an internal inconsistency in the ARU findings. Collagen is reported to improve hydration, measured in the skin’s outer layer, yet roughness — also an outer-layer outcome — did not improve simultaneously. She noted that “critical variables which significantly impact skin ageing, including UV exposure, smoking, sleep, environment and hormonal status, are not accounted for with any consistency in the existing literature.”

What actually happens when collagen is digested

Most collagen products make a specific claim: that ingesting collagen replenishes the body’s own supply. This mechanism does not hold. Collagen is a large structural protein; digestion breaks it down into amino acids and smaller fragments before absorption. Intact collagen molecules never reach skin tissue.

Recent research offers a partial counter-argument. A 2023 PMC review covering 26 trials and 1,721 patients found that specific peptides produced during digestion — including one called Gly-Pro-Hyp — are detectable in blood and skin tissue after supplementation. A 2024 Frontiers in Nutrition study confirmed that these peptides reach the bloodstream, with results varying by source and molecular weight.

The second study was funded by Rousselot BV, a major collagen manufacturer — the same funding dynamic seen throughout this evidence base. The proposed mechanism is that these surviving peptides act as messengers, prompting skin cells to produce more collagen, rather than the supplement replenishing it directly.

Dr Farah Moustafa, Assistant Professor at Tufts University School of Medicine and a dermatologist at Tufts Medical Center, assessed the clinical position plainly: “Oral collagen supplements are not currently recommended to treat skin aging, although they can be considered along with other more effective and well-studied interventions.”

A plausible mechanism is not a proven effect. A proven effect in a specific subgroup is not evidence for the general adult market. That distinction is absent from most product packaging.

Claims and evidence

Popular claim	What the evidence shows
“Clinically proven to reduce wrinkles”	ARU independent review (113 trials, ~8,000 participants) found no significant improvement in skin roughness
“Significant, rapid, and full-body anti-ageing”	ARU researchers describe this as overreach; benefits are duration-dependent and specific to subgroups
Positive trials prove efficacy	21 of 23 supporting trials had some form of industry involvement; independent trials showed no significant effect
“Replenishes skin’s collagen from within”	Collagen is broken down during digestion; proposed mechanism is peptide messaging, not direct replacement
Suitable for all adults over 25	ARU review finds strongest evidence only for postmenopausal women and those with UV-damaged skin
“Trusted by dermatologists” / “supported by science”	No collagen health claims are authorised on the GB Nutrition and Health Claims Register; the ASA has banned multiple UK ads for unsubstantiated claims